Literature DB >> 21272924

Overexpression of Thy1/CD90 in human hepatocellular carcinoma is associated with HBV infection and poor prognosis.

Jeng-Wei Lu1, Jan-Gowth Chang, Kun-Tu Yeh, Rong-Ming Chen, Jeffrey J P Tsai, Rouh-Mei Hu.   

Abstract

Thy1/CD90 is an important marker of many types of stem cells. It functions as a tumor suppressor in ovarian cancer and in nasopharyngeal carcinoma. In this study, the expression status of Thy1 in clinical hepatocellular carcinoma (HCC) tissue samples was investigated. Relationships of Thy1 expression with clinical parameters and patient survival rate were analyzed. The quantities of Thy1 mRNA were statistically higher in tumor tissues than those in the adjacent non-tumor tissues (p<0.001). Immunohistochemical data confirmed that Thy1 protein was increased in 73% of HCC samples. Thy1 expression was not influenced by chronic alcohol exposure or cirrhosis. Overexpression in Thy1 was correlated with age (p=0.006), hepatitis B virus (HBV) infection (p=0.044), and histological grade (p=0.014). Patients with the highest level of Thy1 expression showed the poorest prognosis (p=0.040). In conclusion, overexpression of Thy1 may not suppress the development of HCC. Thy1 could provide a clinical prognostic marker for HCC. Copyright Â
© 2011 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21272924     DOI: 10.1016/j.acthis.2011.01.001

Source DB:  PubMed          Journal:  Acta Histochem        ISSN: 0065-1281            Impact factor:   2.479


  29 in total

Review 1.  Cervical cancer stem cells: opportunities and challenges.

Authors:  Ravindresh Chhabra
Journal:  J Cancer Res Clin Oncol       Date:  2015-01-07       Impact factor: 4.553

2.  Heterogeneity of The CD90+ Population in Different Stages of Hepatocarcinogenesis.

Authors:  Smathorn Thakolwiboon; Jianhui Zhu; Qixing Liang; Theodore H Welling; Min Zhang; David M Lubman
Journal:  J Proteomics Bioinform       Date:  2014-09-12

Review 3.  Cancer stem cell marker glycosylation: Nature, function and significance.

Authors:  Brody W Mallard; Joe Tiralongo
Journal:  Glycoconj J       Date:  2017-06-17       Impact factor: 2.916

4.  Surface markers of liver cancer stem cells and innovative targeted-therapy strategies for HCC.

Authors:  Lige Qiu; Hailiang Li; Sirui Fu; Xiaofang Chen; Ligong Lu
Journal:  Oncol Lett       Date:  2017-12-08       Impact factor: 2.967

5.  Clinical implications of deregulated CDK4 and Cyclin D1 expression in patients with human hepatocellular carcinoma.

Authors:  Jeng-Wei Lu; Yueh-Min Lin; Jan-Gowth Chang; Kun-Tu Yeh; Rong-Ming Chen; Jeffrey J P Tsai; Wei-Wen Su; Rouh-Mei Hu
Journal:  Med Oncol       Date:  2013-01-05       Impact factor: 3.064

6.  Increased expression of PRL-1 protein correlates with shortened patient survival in human hepatocellular carcinoma.

Authors:  J-W Lu; J-G Chang; K-T Yeh; R-M Chen; J J P Tsai; W-W Su; R-M Hu
Journal:  Clin Transl Oncol       Date:  2012-04       Impact factor: 3.405

Review 7.  Clinical implications of cancer stem cell biology in hepatocellular carcinoma.

Authors:  Junfang Ji; Xin Wei Wang
Journal:  Semin Oncol       Date:  2012-08       Impact factor: 4.929

Review 8.  Multiple roles of CD90 in cancer.

Authors:  Atul Kumar; Anshuman Bhanja; Jina Bhattacharyya; Bithiah Grace Jaganathan
Journal:  Tumour Biol       Date:  2016-06-23

Review 9.  Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma.

Authors:  Caecilia H C Sukowati; Korri E El-Khobar; Susan I Ie; Beatrice Anfuso; David H Muljono; Claudio Tiribelli
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

10.  Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma.

Authors:  Taro Yamashita; Masao Honda; Yasunari Nakamoto; Masayo Baba; Kouki Nio; Yasumasa Hara; Sha Sha Zeng; Takehiro Hayashi; Mitsumasa Kondo; Hajime Takatori; Tatsuya Yamashita; Eishiro Mizukoshi; Hiroko Ikeda; Yoh Zen; Hiroyuki Takamura; Xin Wei Wang; Shuichi Kaneko
Journal:  Hepatology       Date:  2013-01-18       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.